In8Bio (INAB) Other Accumulated Expenses (2020 - 2026)
In8Bio (INAB) posted Other Accumulated Expenses of $55000.0 for Q1 2026, down 12.7% sequentially from $63000.0 in Q4 2025, and down 76.09% YoY from $230000.0 in Q1 2025.
In8Bio (INAB) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
In8Bio has reported Other Accumulated Expenses for 7 years, with the latest figure at $55000.0 in Q1 2026.
- Quarterly Other Accumulated Expenses fell 76.09% year-over-year to $55000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55000.0 (down 76.09% YoY) and the FY2025 annual result came in at $63000.0, down 51.91% from the prior year.
- Other Accumulated Expenses slipped to $55000.0 in Q1 2026 per INAB's latest filing, from $63000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $431000.0 in Q2 2022 and troughed at $5000.0 in Q3 2025.
- A 5-year average of $242529.4 and a median of $281000.0 in 2024 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2025: Other Accumulated Expenses soared 1005.13% in 2022, then sank 96.48% in 2025.
- Over 5 years, Other Accumulated Expenses stood at $418000.0 in 2022, then fell by 14.11% to $359000.0 in 2023, then plunged by 63.51% to $131000.0 in 2024, then sank by 51.91% to $63000.0 in 2025, then slipped by 12.7% to $55000.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $55000.0, $63000.0, and $5000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | In8Bio | 24.34 Mn | 24.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21,000.00 |
| Mar 31, 2026 | 55,000.00 |
| Dec 31, 2025 | 63,000.00 |
| Sep 30, 2025 | 5,000.00 |
| Jun 30, 2025 | 59,000.00 |
| Mar 31, 2025 | 230,000.00 |
| Dec 31, 2024 | 131,000.00 |
| Sep 30, 2024 | 142,000.00 |
| Jun 30, 2024 | 281,000.00 |
| Mar 31, 2024 | 183,000.00 |
| Dec 31, 2023 | 359,000.00 |
| Sep 30, 2023 | 319,000.00 |
| Jun 30, 2023 | 386,000.00 |
| Mar 31, 2023 | 407,000.00 |
| Dec 31, 2022 | 418,000.00 |
| Sep 30, 2022 | 294,000.00 |
| Jun 30, 2022 | 431,000.00 |
| Mar 31, 2022 | 360,000.00 |
| Dec 31, 2021 | 51,000.00 |
| Sep 30, 2021 | 202,000.00 |